Teva Pharmaceutical Industries Ltd. $TEVA Holdings Raised by Phoenix Financial Ltd.

Phoenix Financial Ltd. boosted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 9.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 41,295,244 shares of the company’s stock after purchasing an additional 3,533,800 shares during the quarter. Teva Pharmaceutical Industries makes up 11.0% of Phoenix Financial Ltd.’s portfolio, making the stock its biggest holding. Phoenix Financial Ltd. owned 3.60% of Teva Pharmaceutical Industries worth $834,164,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Cromwell Holdings LLC grew its holdings in Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in Teva Pharmaceutical Industries during the second quarter worth approximately $41,000. Sound Income Strategies LLC boosted its holdings in Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after acquiring an additional 2,824 shares during the last quarter. JTC Employer Solutions Trustee Ltd acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $65,000. Finally, MAI Capital Management grew its stake in Teva Pharmaceutical Industries by 26.8% during the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after buying an additional 697 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TEVA. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, December 22nd. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Jefferies Financial Group upped their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. Finally, Scotiabank initiated coverage on Teva Pharmaceutical Industries in a research report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and an average target price of $33.67.

Teva Pharmaceutical Industries Trading Up 1.0%

Shares of TEVA stock opened at $32.11 on Tuesday. The stock has a 50-day simple moving average of $29.79 and a 200 day simple moving average of $22.78. The stock has a market capitalization of $36.83 billion, a P/E ratio of 53.52, a P/E/G ratio of 1.82 and a beta of 0.66. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $33.42.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. This trade represents a 68.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 622,060 shares of company stock worth $17,076,965. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.